HCV-associated Marginal Zone Lymphoma · line 1 · Sofosbuvir/Velpatasvir 12 weeks

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-DAA-SOF-VEL`

ID	`IND-HCV-MZL-1L-ANTIVIRAL`
Type	Indication
Status	reviewed 2026-04-24 \| pending_clinical_signoff
Diseases	`DIS-HCV-MZL`
Sources	`SRC-EASL-HCV-2023` `SRC-ESMO-LYMPHOMA-2025` `SRC-MOZ-UA-LYMPH-2013` `SRC-NCCN-BCELL-2025`

Notes

STUB — requires clinical co-lead signoff before publication. Content for reference case "Patient Zero" per specs/REFERENCE_CASE_SPECIFICATION.md.

Used By

Actionability

BMA-HCV-RNA-MONITORING-DAA-RESPONSE - Quantitative HCV RNA monitoring during direct-acting antiviral (DAA) therapy: pretreatmen...

Algorithms

ALGO-HCV-MZL-1L - ALGO-HCV-MZL-1L

Indication

IND-CHRONIC-HCV-PREVENTION-DAA - IND-CHRONIC-HCV-PREVENTION-DAA
IND-HCV-MZL-1L-BR-AGGRESSIVE - IND-HCV-MZL-1L-BR-AGGRESSIVE

Questionnaires

QUEST-HCV-MZL-1L - HCV-associated Marginal Zone Lymphoma — first line

Red flag

RF-CHRONIC-HCV-NHL-PREVENTION-OPPORTUNITY - Chronic HCV infection (HCV-RNA detectable / persistent viremia) in an individual without...